Home » Prices » LON:CIR

Circassia Pharmaceuticals PLC LON:CIR

Today's live share price, quote history, chart & news

0.24 GBP
-0.02 (-7.69%)
Key Stats
Price open
Previous close 0.26
Market cap 0
Volume 0
Day high 0.28
Day low 0.1293
Year high 0.3
Year low 0.12
Year to date change 18.63%
P/E Ratio N.A
Company Profile
Insider Information

About Circassia Pharmaceuticals PLC

Circassia Pharmaceuticals PLC is a biopharmaceutical company focused on the development and distribution of a wide range of immunotherapies. The company is working on expanding its portfolio through licensing, partnerships, and acquisitions in key markets.

Founded in 2006 by Steve Harris and Charles Swingland, the company operates under two segments. The company’s lead products are NIOX and NIOX VERO. The two are finding great use in the diagnosis and treatment of asthma. Circassia also offers Turdoza a novel medication for chronic obstructive pulmonary disease. The specialty pharmaceutical company distributes its products through specialists in the U.S., the U.K., China, and Germany.

 Circassia Pharmaceuticals PLC has also inked strategic collaboration with AstraZeneca for Turdoza and Duaklir. The company has its headquarters in Oxford the United Kingdom and is listed on the London Stock Exchange.

Company information

Company name
Circassia Group Plc
Health Services
Medical/Nursing Services
Steven Harris
Northbrook House, Robert Robinson Avenue The Oxford Science Park, Oxford, Oxfordshire, OX4
United Kingdom
Contact information

Related companies

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.